Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...
News-Medical.Net on MSN6d
Novo Nordisk A/S: Rybelsus® (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus® (oral ...
Obesity and diabetes drugs, particularly semaglutides like Wegovy and Ozempic, may reduce a person’s risk of dementia, a new ...
In the SOUL trial, Rybelsus produced a 14% risk reduction of major adverse cardiovascular events in patients with type 2 ...
Danish pharmaceutical company Novo Nordisk is set to launch its anti-diabetes and weight-loss drug Wegovy in India, aiming to ...
Detailed price information for Lexaria Bioscience Corp WT (LEXXW-Q) from The Globe and Mail including charting and trades.
KOLLAM: Dally Fernandes (name changed) has been using Semaglutide for the past six months to manage her weight. She believes ...
Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus ® (oral semaglutide) significantly reduced the risk of major adverse ...
Bagsværd, Denmark Tuesday, April 1, 2025, 18:00 Hrs [IST] ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback